Top

07-11-2024 | Neurotomy | Review

The road to renal denervation for hypertension and beyond (HF): two decades of failed, succeeded, and to be determined

Authors: Haoran Jiang, Veraprapas Kittipibul, Felix Mahfoud, Michael Böhm, Paul A. Sobotka, Murray Esler, Jie Wang, Marat Fudim

Published in: Heart Failure Reviews

Abstract

Activation of the sympathetic nervous system has been attributed to the development of hypertension. Two established approaches for treating hypertension are pharmacotherapy and lifestyle changes. With an improved understanding of renal nerve anatomy and physiology, renal denervation has been proposed as an alternative treatment for hypertension. Specifically, it has been shown that the interruption of sympathetic nerves connecting the kidney and the sympathetic nervous system can reduce blood pressure. Here, we present a review on how renal denervation can help hypertension patients, specifically focusing on our novel understanding of renal nerve anatomy, denervation technique, and subsequent clinical trials, and how it may be used to treat other cardiovascular diseases like heart failure.

Kirkland EB, Heincelman M, Bishu KG, et al (2018) Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003–2014. J Am Heart Assoc 2018;7(11). https://doi.org/10.1161/JAHA.118.008731.

Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief 2020(364):1–8. (https://www.ncbi.nlm.nih.gov/pubmed/32487290).

Whelton PK, Carey RM, Aronow WS et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertension 71(6):1269–1324. https://doi.org/10.1161/HYP.0000000000000066CrossRefPubMed

Persell SD (2011) Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 57(6):1076–1080. https://doi.org/10.1161/HYPERTENSIONAHA.111.170308CrossRefPubMed

Carey RM, Calhoun DA, Bakris GL et al (2018) Resistant hypertension: detection, evaluation, and management: a scientific statement from the american heart association. Hypertension 72(5):e53–e90. https://doi.org/10.1161/HYP.0000000000000084CrossRefPubMed

Fudim M, Sobotka AA, Yin YH, et al. Selective vs. global renal denervation: a case for less is more. Curr Hypertens Rep 2018;20(5):37. https://doi.org/10.1007/s11906-018-0838-2.

Barbato E, Azizi M, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention 2023;18(15):1227–1243. https://doi.org/10.4244/EIJ-D-22-00723.

DiBona GF, Kopp UC (1997) Neural control of renal function. Physiol Rev 77(1):75–197. https://doi.org/10.1152/physrev.1997.77.1.75CrossRefPubMed

Atherton DS, Deep NL, Mendelsohn FO (2012) Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study. Clin Anat 25(5):628–633. https://doi.org/10.1002/ca.21280CrossRefPubMed

10.

Sata Y, Head GA, Denton K, May CN, Schlaich MP (2018) Role of the sympathetic nervous system and its modulation in renal hypertension. Front Med (Lausanne) 5:82. https://doi.org/10.3389/fmed.2018.00082CrossRefPubMed

11.

Osborn JW, Foss JD (2017) Renal nerves and long-term control of arterial pressure. Compr Physiol 7(2):263–320. https://doi.org/10.1002/cphy.c150047CrossRefPubMed

12.

Osborn JW, Tyshynsky R, Vulchanova L (2021) Function of renal nerves in kidney physiology and pathophysiology. Annu Rev Physiol 83:429–450. https://doi.org/10.1146/annurev-physiol-031620-091656CrossRefPubMed

13.

Moyer JM, Handley CA (1952) Norepinephrine and epinephrine effect on renal hemodynamics, with particular reference to the possibility of vascular shunting and decreasing the active glomeruli. Circulation 5(1):91–97. https://doi.org/10.1161/01.cir.5.1.91CrossRefPubMed

14.

Johnson JA, Davis JO, Witty RT (1971) Effects of catecholamines and renal nerve stimulation on renin release in the nonfiltering kidney. Circ Res 29(6):646–653. https://doi.org/10.1161/01.res.29.6.646CrossRefPubMed

15.

Hesse IF, Johns EJ (1984) The subtype of alpha-adrenoceptor involved in the neural control of renal tubular sodium reabsorption in the rabbit. J Physiol 352:527–538. https://doi.org/10.1113/jphysiol.1984.sp015308CrossRefPubMedPubMedCentral

16.

Edlund A, Sollevi A. Renal effects of i.v. adenosine infusion in humans. Clin Physiol 1993;13(4):361–71. https://doi.org/10.1111/j.1475-097x.1993.tb00336.x.

17.

Choi MR, Kouyoumdzian NM, Rukavina Mikusic NL et al (2015) Renal dopaminergic system: pathophysiological implications and clinical perspectives. World J Nephrol 4(2):196–212. https://doi.org/10.5527/wjn.v4.i2.196CrossRefPubMedPubMedCentral

18.

Norvell JE, Anderson JM (1983) Assessment of possible parasympathetic innervation of the kidney. J Auton Nerv Syst 8(3):291–294. https://doi.org/10.1016/0165-1838(83)90112-1CrossRefPubMed

19.

Gattone VH 2nd, Marfurt CF, Dallie S (1986) Extrinsic innervation of the rat kidney: a retrograde tracing study. Am J Physiol 250(2 Pt 2):F189–F196. https://doi.org/10.1152/ajprenal.1986.250.2.F189CrossRefPubMed

20.

Barajas L, Wang P (1975) Demonstration of acetylcholinesterase in the adrenergic nerves of the renal glomerular arterioles. J Ultrastruct Res 53(2):244–253. https://doi.org/10.1016/s0022-5320(75)80141-9CrossRefPubMed

21.

van Amsterdam WA, Blankestijn PJ, Goldschmeding R, Bleys RL (2016) The morphological substrate for renal denervation: nerve distribution patterns and parasympathetic nerves. A post-mortem histological study Ann Anat 204:71–79. https://doi.org/10.1016/j.aanat.2015.11.004CrossRefPubMed

22.

Cheng X, Zhang Y, Chen R et al (2022) Anatomical evidence for parasympathetic innervation of the renal vasculature and pelvis. J Am Soc Nephrol 33(12):2194–2210. https://doi.org/10.1681/ASN.2021111518CrossRefPubMedPubMedCentral

23.

Liu H, Li Y, Zhou H et al (2023) Renal nerve stimulation identifies renal innervation and optimizes the strategy for renal denervation in canine. J Transl Med 21(1):100. https://doi.org/10.1186/s12967-023-03919-9CrossRefPubMedPubMedCentral

24.

Murai H, Okuyama Y, Sakata Y et al (2015) Different responses of arterial blood pressure to electrical stimulation of the renal artery in patients with resistant hypertension. Int J Cardiol 190:296–298. https://doi.org/10.1016/j.ijcard.2015.04.196CrossRefPubMed

25.

Kopp UC, Cicha MZ, Smith LA, Hokfelt T (2001) Nitric oxide modulates renal sensory nerve fibers by mechanisms related to substance P receptor activation. Am J Physiol Regul Integr Comp Physiol 281(1):R279–R290. https://doi.org/10.1152/ajpregu.2001.281.1.R279CrossRefPubMed

26.

Ditting T, Tiegs G, Rodionova K et al (2009) Do distinct populations of dorsal root ganglion neurons account for the sensory peptidergic innervation of the kidney? Am J Physiol Renal Physiol 297(5):F1427–F1434. https://doi.org/10.1152/ajprenal.90599.2008CrossRefPubMed

27.

Kopp UC (2015) Role of renal sensory nerves in physiological and pathophysiological conditions. Am J Physiol Regul Integr Comp Physiol 308(2):R79-95. https://doi.org/10.1152/ajpregu.00351.2014CrossRefPubMed

28.

Lee S, Malykhina AP. Neuro-tracing approach to study kidney innervation: a technical note. Kidney Res Clin Pract 2017;36(1):86–94. https://doi.org/10.23876/j.krcp.2017.36.1.86.

29.

Knuepfer MM, Schramm LP (1987) The conduction velocities and spinal projections of single renal afferent fibers in the rat. Brain Res 435(1–2):167–173. https://doi.org/10.1016/0006-8993(87)91598-8CrossRefPubMed

30.

Zheng H, Patel KP (2017) Integration of renal sensory afferents at the level of the paraventricular nucleus dictating sympathetic outflow. Auton Neurosci 204:57–64. https://doi.org/10.1016/j.autneu.2016.08.008CrossRefPubMed

31.

Cao W, Yang Z, Liu X et al (2023) A kidney-brain neural circuit drives progressive kidney damage and heart failure. Signal Transduct Target Ther 8(1):184. https://doi.org/10.1038/s41392-023-01402-xCrossRefPubMedPubMedCentral

32.

Simon OR, Schramm LP (1984) The spinal course and medullary termination of myelinated renal afferents in the rat. Brain Res 290(2):239–247. https://doi.org/10.1016/0006-8993(84)90941-7CrossRefPubMed

33.

Recordati GM, Moss NG, Waselkov L (1978) Renal chemoreceptors in the rat. Circ Res 43(4):534–543. https://doi.org/10.1161/01.res.43.4.534CrossRefPubMed

34.

Nijima A (1971) Afferent discharges from arterial mechanoreceptors in the kidney of the rabbit. J Physiol 219(2):477–485. https://doi.org/10.1113/jphysiol.1971.sp009673CrossRefPubMed

35.

Zheng F, Lawson SN (1997) Neurokinin A in rat renal afferent neurons and in nerve fibres within smooth muscle and epithelium of rat and guinea-pig renal pelvis. Neuroscience 76(4):1245–1255. https://doi.org/10.1016/s0306-4522(96)00441-1CrossRefPubMed

36.

Recordati G, Moss NG, Genovesi S, Rogenes P (1981) Renal chemoreceptors. J Auton Nerv Syst 3(2–4):237–251. https://doi.org/10.1016/0165-1838(81)90066-7CrossRefPubMed

37.

Ashton N, Clarke CG, Eddy DE, Swift FV (1994) Mechanisms involved in the activation of ischemically sensitive, afferent renal nerve mediated reflex increases in hind-limb vascular resistance in the anesthetized rabbit. Can J Physiol Pharmacol 72(6):637–643. https://doi.org/10.1139/y94-090CrossRefPubMed

38.

Kottke FJ, Kubicek WG, Visscher MB (1945) The production of arterial hypertension by chronic renal artery-nerve stimulation. Am J Physiol 145:38–47. https://doi.org/10.1152/ajplegacy.1945.145.1.38CrossRefPubMed

39.

Smithwick RH, Thompson JE (1953) Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 152(16):1501–1504. https://doi.org/10.1001/jama.1953.03690160001001CrossRefPubMed

40.

Esler M, Jennings G, Korner P et al (1988) Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 11(1):3–20. https://doi.org/10.1161/01.hyp.11.1.3CrossRefPubMed

41.

Levin HR, Gelfand M. Renal nerve stimulation method for treatment of patients. Ardian Inc; 2007.

42.

Roubsanthisuk W, Kunanon S, Chattranukulchai P et al (2023) 2022 Renal denervation therapy for the treatment of hypertension: a statement from the thai hypertension society. Hypertens Res 46(4):898–912. https://doi.org/10.1038/s41440-022-01133-6CrossRefPubMedPubMedCentral

43.

Wilson AL, Gandhi J, Suh Y, Joshi G, Smith NL, Khan SA (2020) Renal innervation in resistant hypertension: a review of pathophysiology and renal denervation as potential treatment. Curr Hypertens Rev 16(2):115–127. https://doi.org/10.2174/1573402115666190301154100CrossRefPubMedPubMedCentral

44.

Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Bohm M, Krum H (2011) Sympatho-renal axis in chronic disease. Clin Res Cardiol 100(12):1049–1057. https://doi.org/10.1007/s00392-011-0335-yCrossRefPubMedPubMedCentral

45.

Liard JF (1977) Renal denervation delays blood pressure increase in the spontaneously hypertensive rat. Experientia 33(3):339–340. https://doi.org/10.1007/BF02002815CrossRefPubMed

46.

Kline RL, Kelton PM, Mercer PF (1978) Effect of renal denervation on the development of hypertension in spontaneously hypertensive rats. Can J Physiol Pharmacol 56(5):818–822. https://doi.org/10.1139/y78-128CrossRefPubMed

47.

Wyss JM, Aboukarsh N, Oparil S (1986) Sensory denervation of the kidney attenuates renovascular hypertension in the rat. Am J Physiol 250(1 Pt 2):H82–H86. https://doi.org/10.1152/ajpheart.1986.250.1.H82CrossRefPubMed

48.

Banek CT, Knuepfer MM, Foss JD et al (2016) Resting afferent renal nerve discharge and renal inflammation: elucidating the role of afferent and efferent renal nerves in deoxycorticosterone acetate salt hypertension. Hypertension 68(6):1415–1423. https://doi.org/10.1161/HYPERTENSIONAHA.116.07850CrossRefPubMed

49.

Foss JD, Fink GD, Osborn JW (2016) Differential role of afferent and efferent renal nerves in the maintenance of early- and late-phase Dahl S hypertension. Am J Physiol Regul Integr Comp Physiol 310(3):R262–R267. https://doi.org/10.1152/ajpregu.00408.2015CrossRefPubMed

50.

Grimson KS (1941) Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg 114(4):753–775. https://doi.org/10.1097/00000658-194111440-00018CrossRefPubMedPubMedCentral

51.

Craig WM (1939) Surgical treatment of hypertension. Br Med J 2(4120):1215–1219. https://doi.org/10.1136/bmj.2.4120.1215CrossRefPubMedPubMedCentral

52.

Grimson KS, Orgain ES, Anderson B, Broome RA, Longino FH. Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy. Ann Surg 1949;129(6):850–71. (https://www.ncbi.nlm.nih.gov/pubmed/17859363).

53.

Mountfort K, Mahfoud F, Schmieder R, et al. Catheter-based renal sympathetic denervation - long-term symplicity renal denervation clinical evidence, new data and future perspectives. Interv Cardiol 2013;8(2):118–123. https://doi.org/10.15420/icr.2013.8.2.118.

54.

Sato Y, Kawakami R, Sakamoto A et al (2021) Paradise ultrasound renal denervation system for the treatment of hypertension. Future Cardiol 17(6):931–944. https://doi.org/10.2217/fca-2020-0228CrossRefPubMed

55.

Fischell TA, Ebner A, Gallo S et al (2016) Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-in-human experience. JACC Cardiovasc Interv 9(6):589–598. https://doi.org/10.1016/j.jcin.2015.11.041CrossRefPubMed

56.

Krum H, Schlaich MP, Sobotka PA et al (2014) Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the symplicity HTN-1 study. Lancet 383(9917):622–629. https://doi.org/10.1016/S0140-6736(13)62192-3CrossRefPubMed

57.

Esler MD, Bohm M, Sievert H et al (2014) Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the symplicity htn-2 randomized clinical trial. Eur Heart J 35(26):1752–1759. https://doi.org/10.1093/eurheartj/ehu209CrossRefPubMedPubMedCentral

58.

Mahfoud F, Bohm M, Schmieder R et al (2019) Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the global symplicity registry. Eur Heart J 40(42):3474–3482. https://doi.org/10.1093/eurheartj/ehz118CrossRefPubMedPubMedCentral

59.

Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671):1275–1281. https://doi.org/10.1016/S0140-6736(09)60566-3CrossRefPubMed

60.

Symplicity HTNI, Esler MD, Krum H et al (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376(9756):1903–1909. https://doi.org/10.1016/S0140-6736(10)62039-9CrossRef

61.

Bhatt DL, Kandzari DE, O’Neill WW et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370(15):1393–1401. https://doi.org/10.1056/NEJMoa1402670CrossRefPubMed

62.

Kandzari DE, Bhatt DL, Brar S et al (2015) Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 36(4):219–227. https://doi.org/10.1093/eurheartj/ehu441CrossRefPubMed

63.

Bakris GL, Townsend RR, Flack JM et al (2015) 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol 65(13):1314–1321. https://doi.org/10.1016/j.jacc.2015.01.037CrossRefPubMed

64.

Osborn JW, Banek CT (2018) Catheter-based renal nerve ablation as a novel hypertension therapy: lost, and then found, in translation. Hypertension 71(3):383–388. https://doi.org/10.1161/HYPERTENSIONAHA.117.08928CrossRefPubMed

65.

Bhatt DL, Vaduganathan M, Kandzari DE et al (2022) Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 400(10361):1405–1416. https://doi.org/10.1016/S0140-6736(22)01787-1CrossRefPubMed

66.

Azizi M, Sapoval M, Gosse P et al (2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385(9981):1957–1965. https://doi.org/10.1016/S0140-6736(14)61942-5CrossRefPubMed

67.

Kandzari DE, Kario K, Mahfoud F et al (2016) The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J 171(1):82–91. https://doi.org/10.1016/j.ahj.2015.08.021CrossRefPubMed

68.

Kandzari DE, Bohm M, Mahfoud F et al (2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391(10137):2346–2355. https://doi.org/10.1016/S0140-6736(18)30951-6CrossRefPubMed

69.

Kandzari DE, Townsend RR, Kario K et al (2023) Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol 82(19):1809–1823. https://doi.org/10.1016/j.jacc.2023.08.045CrossRefPubMed

70.

Townsend RR, Mahfoud F, Kandzari DE et al (2017) Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 390(10108):2160–2170. https://doi.org/10.1016/S0140-6736(17)32281-XCrossRefPubMed

71.

Bohm M, Kario K, Kandzari DE et al (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 395(10234):1444–1451. https://doi.org/10.1016/S0140-6736(20)30554-7CrossRefPubMed

72.

Azizi M, Schmieder RE, Mahfoud F et al (2018) Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 391(10137):2335–2345. https://doi.org/10.1016/S0140-6736(18)31082-1CrossRefPubMed

73.

Azizi M, Saxena M, Wang Y et al (2023) Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA 329(8):651–661. https://doi.org/10.1001/jama.2023.0713CrossRefPubMedPubMedCentral

74.

Azizi M, Sanghvi K, Saxena M et al (2021) Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 397(10293):2476–2486. https://doi.org/10.1016/S0140-6736(21)00788-1CrossRefPubMed

75.

Kario K, Yokoi Y, Okamura K et al (2022) Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res 45(2):221–231. https://doi.org/10.1038/s41440-021-00754-7CrossRefPubMed

76.

Mahfoud F, Renkin J, Sievert H et al (2020) Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension. JACC Cardiovasc Interv 13(4):471–484. https://doi.org/10.1016/j.jcin.2019.10.048CrossRefPubMed

77.

Kandzari DE, Weber MA, Pathak A et al (2024) Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive medications: primary results from the TARGET BP I randomized clinical trial. Circulation 149(24):1875–1884. https://doi.org/10.1161/CIRCULATIONAHA.124.069291CrossRefPubMed

78.

Pathak A, Rudolph UM, Saxena M et al (2023) Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications. EuroIntervention 19(7):602–611. https://doi.org/10.4244/EIJ-D-23-00088CrossRefPubMedPubMedCentral

79.

Wang J, Yin Y, Lu C et al (2024) Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial. EClinicalMedicine 72:102626. https://doi.org/10.1016/j.eclinm.2024.102626CrossRefPubMedPubMedCentral

80.

Niiranen TJ, Maki J, Puukka P, Karanko H, Jula AM (2014) Office, home, and ambulatory blood pressures as predictors of cardiovascular risk. Hypertension 64(2):281–286. https://doi.org/10.1161/HYPERTENSIONAHA.114.03292CrossRefPubMed

81.

Sharp ASP, Tunev S, Schlaich M et al (2022) Histological evidence supporting the durability of successful radiofrequency renal denervation in a normotensive porcine model. J Hypertens 40(10):2068–2075. https://doi.org/10.1097/HJH.0000000000003236CrossRefPubMedPubMedCentral

82.

Booth LC, Nishi EE, Yao ST, et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension 2015;65(2):393–400. https://doi.org/10.1161/HYPERTENSIONAHA.114.04176.

83.

Al Ghorani H, Kulenthiran S, Recktenwald MJM et al (2023) 10-year outcomes of catheter-based renal denervation in patients with resistant hypertension. J Am Coll Cardiol 81(5):517–519. https://doi.org/10.1016/j.jacc.2022.11.038CrossRefPubMed

84.

Mahfoud F, Townsend RR, Kandzari DE et al (2021) Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol 77(23):2909–2919. https://doi.org/10.1016/j.jacc.2021.04.044CrossRefPubMed

85.

Fudim M, Sobotka PA, Piccini JP, Patel MR (2021) Renal denervation for patients with heart failure: making a full circle. Circ Heart Fail 14(3):e008301. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008301CrossRefPubMed

86.

Bohm M, Ewen S, Kindermann I, Linz D, Ukena C, Mahfoud F (2014) Renal denervation and heart failure. Eur J Heart Fail 16(6):608–613. https://doi.org/10.1002/ejhf.83CrossRefPubMed

87.

Davies JE, Manisty CH, Petraco R et al (2013) First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 162(3):189–192. https://doi.org/10.1016/j.ijcard.2012.09.019CrossRefPubMed

88.

Wang J, Sun N, Ge J et al (2023) Rationale and design of sympathetic mapping/ablation of renal nerves trial (SMART) for the treatment of hypertension: a prospective, multicenter, single-blind, randomized and sham procedure-controlled study. J Cardiovasc Transl Res 16(2):358–370. https://doi.org/10.1007/s12265-022-10307-zCrossRefPubMed

Title: The road to renal denervation for hypertension and beyond (HF): two decades of failed, succeeded, and to be determined
Authors: Haoran Jiang
Veraprapas Kittipibul
Felix Mahfoud
Michael Böhm
Paul A. Sobotka
Murray Esler
Jie Wang
Marat Fudim
Publication date: 07-11-2024
Publisher: Springer US
Keywords: Neurotomy
Hypertension
Hypertension
Heart Failure
Published in: Heart Failure Reviews
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-024-10463-1

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

Keynote webinar | Spotlight on medication adherence

Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Watch now

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content

Keynote series | Spotlight on menopause

A quick guide to ECGs

Keynote webinar | Spotlight on medication adherence